HCV-ASSOCIATED LIVER CIRRHOSIS: MODERN POSSIBILITIES OF INTERFERON-FREE THERAPY
- Authors: Bakulin I.G1, Abdurakhmanov D.T2,3, Shalikiani N.V1, Polukhina A.V1, Matveeva Y.A1, Sidorova E.I3, Rozina T.P2, Nikulkina E.N2
-
Affiliations:
- SBHCI “Moscow Clinical Research Center" of Moscow Healthcare Department
- SBEI HPE “First MSMU n.a.I.M.Sechenov" of RMPH
- MSU n.a. M.I. Lomonosov
- Issue: No 2 (2016)
- Pages: 7-11
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/288597
- ID: 288597
Cite item
Open Access
Access granted
Abstract
Full Text
About the authors
I. G Bakulin
SBHCI “Moscow Clinical Research Center" of Moscow Healthcare Department
Email: igbakulin@yandex.ru
MD, Prof., Head of the Department of Hepatology Moscow
D. T Abdurakhmanov
SBEI HPE “First MSMU n.a.I.M.Sechenov" of RMPH; MSU n.a. M.I. LomonosovMoscow
N. V Shalikiani
SBHCI “Moscow Clinical Research Center" of Moscow Healthcare DepartmentMoscow
A. V Polukhina
SBHCI “Moscow Clinical Research Center" of Moscow Healthcare DepartmentMoscow
Yu. A Matveeva
SBHCI “Moscow Clinical Research Center" of Moscow Healthcare DepartmentMoscow
E. I Sidorova
MSU n.a. M.I. LomonosovMoscow
T. P Rozina
SBEI HPE “First MSMU n.a.I.M.Sechenov" of RMPHMoscow
E. N Nikulkina
SBEI HPE “First MSMU n.a.I.M.Sechenov" of RMPHMoscow
References
- Бакулин И.Г., Галушко М.Ю. Противовирусная терапия хронического гепатита С: состояние вопроса. http://www.hcv.ru/
- Абдурахманов Д.Т., Морозов В.Г. Безопасность и эффективность телапревира в лечении хронического гепатита С у больных российской популяции, включенных в исследование по программе раннего доступа. РЖГГК. 2014;24(1):39-46.
- Manns M., Pol M., Jacobson I.M., et al. Alloral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014;384( 9954): 1597-605.
- Kao J-H., Heo J., Yoffe B., Sievert W., Jacobson I.M., Bessone F., Peng C-Y., Roberts S., Yoon K.T., Kopit J., Linaberry M., Noviello S., Hughes E., Manns M. Efficacy and safety of daclatasvir in combination with asunaprevir (DCV+ASV) in cirrhotic and non-cirrhotic patients with HCV genotype 1B: results of the the HALLMARK DUAL study. J. Hepatol. 2014;60(Suppl.):P1300.
- Kumada H., Suzuki Y., Ikeda K., Toyota J., Karino Y., Chayama K., Kawakami Y., Ido A., Yamamoto K., Takaguchi K., Izumi N., Koike K., Takehara T., Kawada N., Sata M., Miyagoshi H., Eley T., McPhee F., Damokosh A., Ishikawa H., Hughes E. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59(6):2083-91.
- Wei L., Zhang M.X., еt al. Daclatasvir and Asunaprevir in Non-Japanese Asian Patients with Chronic HCV Genotype 1b Infection who are Ineligible for or Intolerant to Interferonalfa Therapies With or Without Ribavirin: Phase 2015;3 SVR12 Interim Results. ASLD.
Supplementary files
